http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#Head http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#provenance http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#pubinfo http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB09331 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association http://www.w3.org/2000/01/rdf-schema#label darzalex is indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent darzalex is a cd38 directed cytolytic antibody indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent 1 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB09331 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#provenance http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#pubinfo http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig http://purl.org/nanopub/x/hasSignature W87Ykj7wWgb+O9M9lwPLu9faZ7KvyGzXMiu4hbMaA5rdWBehXMCMQ9oXYRJ7cWQ1MrWpUajUnIu6iy7dpDV9AtwDBPD9Cz1CdIa3gbK1YUUv9CMbgFI0HrMJoqrX6xYdw3CXa92s7QqIUROH/gzk3j5Dibk3YEGR8AhiNX8OezA= http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://purl.org/dc/terms/created 2021-06-12T12:46:02.775+02:00 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs